Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.52), $0.14 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $147.02 million versus the consensus estimate of $123.2 million.

GUIDANCE:

Ultragenyx Pharma sees FY2024 revenue of $530-550 million, versus the consensus of $512 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.